Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy

Published:2015-05-01 Issue:7 Volume:28 Page:913-920
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Mod Pathol

Author:

Peintinger Florentia,Sinn Bruno,Hatzis Christos,Albarracin Constance,Downs-Kelly Erinn,Morkowski Jerzy,Gould Rebekah,Symmans W Fraser

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Link

http://www.nature.com/articles/modpathol201553.pdf

Reference20 articles.

1. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672–2685.

2. Kuerer HM, Neuman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460–469.

3. Cortazar P, Zhang L, Untch M et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTneoBC pooled analysis. The Lancet 2014;384:164–172.

4. Provenzano E, Vallier AL, Champ R et al. A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial. Br J Cancer 2013;108:866–872.

5. Symmans WF, Peintinger F, Hatzis C et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007;25:4414–4422.

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic factors of patients with human epidermal growth factor receptor 2-positive breast cancer following neoadjuvant therapy: Development and validation of a predictive nomogram;Pathology - Research and Practice;2024-09

2. Tumor-Infiltrating Lymphocyte Scoring in Neoadjuvant-Treated Breast Cancer;Cancers;2024-08-20

3. Invasive lobular carcinoma of the breast; clinicopathologic profile and response to neoadjuvant chemotherapy over a 15-year period;The Breast;2024-08

4. New Emerging Chemokine Receptors: CCR5 or CXCR5 on Tumor Is Associated with Poor Response to Chemotherapy and Poor Prognosis in Locally Advanced Triple-Negative Breast Cancer;Cancers;2024-06-28

5. Impact of Presenting Stage on Overall Survival in Patients Treated with Neoadjuvant Chemotherapy for Triple Negative Breast Cancer;Annals of Surgical Oncology;2024-06-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3